Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 747 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07280715Recruiting
Tracking immunotherapy side effects in real time
This study uses a smartphone app to track side effects from immunotherapy (a type of cancer treatment that helps your immune system fight cancer) in people with melanoma. The goal is to better understand and manage these side effects as they happen.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07260370Recruiting
Studying blood markers in cancer patients on immunotherapy
This study looks at tiny particles (microRNA) and cancer cells in the blood of people with cancer who are getting immunotherapy. It aims to find patterns that might help doctors better understand how the treatment is working.
Taoyuan CityAges 20 years+ - NCT07250542RecruitingPhase 2
Fasudil with immunotherapy for advanced prostate cancer
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
NanjingAges 18–85 - NCT05255302RecruitingPhase 2/Phase 3
Shorter immune maintenance for stage IV lung cancer after initial treatment
This trial tests whether giving immune therapy maintenance for a shorter time helps people with stage IV non-small cell lung cancer (NSCLC) who are doing well after initial chemo-immunotherapy. It aims to keep the cancer controlled while possibly reducing treatment exposure and side effects.
Aix-en-ProvenceAges 18–74 - NCT07239466RecruitingPhase 2
Ketone supplement with radiation and chemo for rectal cancer
This study tests a combination of a special diet supplement (beta-hydroxybutyrate), short radiation therapy, immunotherapy, and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improve treatment outcomes.
Wuhan, HubeiAges 18–75 - NCT07224971RecruitingPhase 2
Timing of immunotherapy for advanced cancer
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06915389Recruiting
Gastric cancer: predicting immune therapy side effects
This trial studies whether blood tests before treatment can predict side effects from immunotherapy (PD-1/PD-L1 inhibitors) in people with gastric cancer. If you are about to start this type of treatment, your participation could help doctors manage side effects better.
Xining, QinghaiAges 18–80 - NCT07204132Recruiting
Freezing and Immunotherapy for Bladder Cancer
This study tests a combination treatment for people with early-stage bladder cancer who want to avoid bladder removal. It uses a freezing technique (cryoablation) inside the bladder along with immunotherapy drugs to see if this can cure the cancer while keeping the bladder.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06930950Recruiting
Cashew allergy treatment study for children
This study tests if giving small, increasing amounts of cashew can help children outgrow their allergy. It may be an option for kids who are allergic to cashew and have had a clear allergic reaction in a food challenge.
HelsinkiAges 1–17 - NCT07198165RecruitingPhase 2
Short radiation followed by chemo plus bevacizumab with or without immunotherapy for rectal cancer
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
ShanghaiAges 18–75 - NCT07166003Recruiting
Immunotherapy before surgery for lung cancer
This trial tests whether giving immunotherapy before surgery helps people with lung cancer. It is for patients who have already started this treatment and are otherwise healthy.
BeijingAges 18–79 - NCT07138547RecruitingPhase 1/Phase 2
Eliglustat plus CD30 immunotherapy for CD30+ lymphoma
This trial tests a combination of two medicines (eliglustat and a CD30-targeted immunotherapy) for people with a type of lymphoma that has a specific marker called CD30. It aims to see if this combination can help when standard treatments have already been used.
Beijing, Beijing MunicipalityAges 18–75 - NCT06035328Recruiting
Comparing different maintenance doses for wheat allergy oral immunotherapy
This study tests whether taking a maintenance dose of wheat oral immunotherapy once or twice a week is more effective for children with wheat allergy. It aims to find the best schedule to keep them protected from allergic reactions.
Bangkoknoi, BangkokAges 5–18 - NCT07131007Recruiting
Early warning system for immunotherapy side effects
This study is for people with cancer who are already receiving immunotherapy (checkpoint inhibitors). It aims to build an early warning system to help detect and manage possible organ damage or other side effects from the treatment, using advanced testing to keep you safer.
Shijiazhuang, HebeiAges 18–80 - NCT07121374RecruitingPhase 1/Phase 2
Chemotherapy and immunotherapy before possible surgery for mesothelioma
This trial tests whether giving chemotherapy and immunotherapy before planned surgery can make inoperable pleural mesothelioma operable. It is for people with a specific type of mesothelioma (epithelioid) that cannot be removed right away, to see if the treatment shrinks the tumor enough for surgery later.
Edegem, AntwerpAges 18 years+ - NCT07109401RecruitingPhase 2
Immunotherapy for early-stage small cell lung cancer that can be removed with surgery
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
ShanghaiAges 18–75 - NCT07113275RecruitingPhase 3
Short versus long radiation schedule for advanced rectal cancer
This study compares two different schedules of radiation (a short course versus a longer course) followed by standard chemotherapy and immunotherapy for advanced rectal cancer. It aims to see which approach works best to shrink the tumor before surgery.
Wuhan, HubeiAges 18–75 - NCT07091305RecruitingPhase 2
Study of a new drug with chemotherapy for limited-stage small cell lung cancer
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
ShanghaiAges 18–75 - NCT07092696RecruitingPhase 2
Immunotherapy and chemoradiation for cervical cancer
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
TianjinAges 18–75 - NCT07080437Recruiting
Immunotherapy and chemoradiation for elderly esophageal cancer patients
This study looks at how safe and effective a combination of immunotherapy (a treatment that helps your immune system fight cancer) and standard chemotherapy plus radiation is for older adults (70+) with a type of esophageal cancer called squamous cell carcinoma who cannot have surgery or choose not to.
Chongqing, Chongqing MunicipalityAges 70 years+ - NCT06218901Recruiting
Psychological distress in lung cancer patients
This study looks at how lung cancer patients experience emotional distress like anxiety or depression. It aims to better understand these feelings and how they affect patients so that support can be improved.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07069842Recruiting
Gastric cancer immunotherapy prediction model
This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.
Changzhi, ShanxiAges 18–75 - NCT07062055RecruitingPhase 2
Combination therapy for advanced liver cancer that has spread
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
Jinan, ShandongAges 18–70 - NCT07052669RecruitingPhase 3
Shorter Chemo-Radiation Plus Immunotherapy for Stage III Lung Cancer
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Chongqing, Chongqing MunicipalityAges 18–75
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 747 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.